Emerging drugs for bronchiectasis: an update

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Expert Opinion on Emerging Drugs

• Publication date

  2015-04-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14728214.2015.1021683PMID 25736583
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pulmonary complications in primary hypogammaglobulinemia: a survey by high resolution CT scan.

  2016cited by this paper
• Muscarinic M3 receptors on structural cells regulate cigarette smoke-induced neutrophilic airway inflammation in mice.

  2015cited by this paper
• Improving immunity to Haemophilus influenzae in children with chronic suppurative lung disease.

  2015cited by this paper
• The Role of Viral Infection in Pulmonary Exacerbations of Bronchiectasis in Adults

  2015cited by this paper
• Developing drug therapies in bronchiectasis

  2015cited by this paper
• Toward Making Inroads in Reducing the Disparity of Lung Health in Australian Indigenous and New Zealand Māori Children

  2015cited by this paper
• Three clinically distinct chronic pediatric airway infections share a common core microbiota.

  2014cited by this paper
• Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled trial.

  2014cited by this paper
• Respiratory viruses in exacerbations of non-cystic fibrosis bronchiectasis in children

  2014cited by this paper
• The bronchiectasis severity index. An international derivation and validation study.

  2014influential reference
• Deletion of airway cilia results in noninflammatory bronchiectasis and hyperreactive airways.

  2014cited by this paper
• Incremental shuttle walking test: a reproducible and valid test to evaluate exercise tolerance in adults with noncystic fibrosis bronchiectasis.

  2014cited by this paper
• Long-term air humidification therapy is cost-effective for patients with moderate or severe chronic obstructive pulmonary disease or bronchiectasis.

  2014cited by this paper
• A novel microbiota stratification system predicts future exacerbations in bronchiectasis.

  2014cited by this paper
• The Sputum Colour Chart as a predictor of lung inflammation, proteolysis and damage in non‐cystic fibrosis bronchiectasis: A case–control analysis

  2014cited by this paper
• Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials.

  2014cited by this paper
• Antimicrobial treatment of non-cystic fibrosis bronchiectasis

  2014cited by this paper
• Quality of Life Questionnaire-Bronchiectasis: final psychometric analyses and determination of minimal important difference scores

  2014cited by this paper
• Bronchiectasis-Associated Hospitalizations in Germany, 2005 – 2011: A Population-Based Study of Disease Burden and Trends

  2014cited by this paper
• Non-typeable Haemophilus influenzae, an under-recognised pathogen.

  2014cited by this paper
• Respiratory exacerbations in indigenous children from two countries with non-cystic fibrosis chronic suppurative lung disease/bronchiectasis.

  2014cited by this paper
• Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial

  2014cited by this paper
• Early Childhood Investments Substantially Boost Adult Health

  2014cited by this paper
• Bronchiectasis: the arrival of better evidence.

  2014cited by this paper
• Combination inhaled corticosteroids and long-acting beta2-agonists for children and adults with bronchiectasis.

  2014cited by this paper
• Combination Inhaled Corticosteroids and Long-Acting Beta2-Agonists for Children and Adults with Bronchiectasis

  2014cited by this paper
• Children with Chronic Suppurative Lung Disease Have a Reduced Capacity to Synthesize Interferon-Gamma In Vitro in Response to Non-Typeable Haemophilus influenzae

  2014cited by this paper
• Biofilm-dependent airway infections: a role for ambroxol?

  2014cited by this paper
• Mucolytics for bronchiectasis.

  2014cited by this paper
• Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition

  2013cited by this paper
• Eight-weekly intravenous antibiotics is beneficial in severe bronchiectasis.

  2013cited by this paper
• Neutrophils and emerging targets for treatment in chronic obstructive pulmonary disease

  2013cited by this paper
• Prevention of respiratory tract infections with bacterial lysate OM-85 bronchomunal in children and adults: a state of the art

  2013cited by this paper
• Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis.

  2013influential reference
• Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis.

  2013cited by this paper
• Resolution of Inflammation: Leukocytes and Molecular Pathways as Potential Therapeutic Targets

  2013cited by this paper
• Bronchoscopy contributes to the clinical management of indigenous children newly diagnosed with bronchiectasis

  2013cited by this paper
• Lung T-cell responses to nontypeable Haemophilus influenzae in patients with chronic obstructive pulmonary disease.

  2013cited by this paper
• Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease.

  2013cited by this paper
• Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation.

  2013cited by this paper
• Efficacy and safety of AZD5069, a CXCR2 antagonist, in adult bronchiectasis

  2013influential reference
• Bronchiectasis-Associated Hospitalizations in Germany, 2005–2011: A Population-Based Study of Disease Burden and Trends

  2013cited by this paper
• Specialty Grand Challenge – Pediatric Pulmonology

  2013cited by this paper
• Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS)

  2013cited by this paper
• Neutrophil extracellular traps (NETs) - formation and implications.

  2013cited by this paper
• Targeting Neutrophil Apoptosis for Enhancing the Resolution of Inflammation

  2013cited by this paper
• Effect of granulocyte‐macrophage colony‐stimulating factor on neutrophil function in idiopathic bronchiectasis

  2013cited by this paper
• Economic Burden of Non-Cystic Fibrosis Bronchiectasis in the First Year after Diagnosis from A US Health Plan Perspective

  2013cited by this paper
• Polyvalent mechanical bacterial lysate for the prevention of recurrent respiratory infections: a meta-analysis.

  2012cited by this paper
• Budesonide efficacy and safety in patients with bronchiectasis not due to cystic fibrosis

  2012cited by this paper
• Lung microbiology and exacerbations in COPD

  2012cited by this paper
• The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis.

  2012cited by this paper
• Defining pulmonary exacerbation in children with non‐cystic fibrosis bronchiectasis

  2012cited by this paper
• Genome-Scale Approaches to Identify Genes Essential for Haemophilus influenzae Pathogenesis

  2012cited by this paper
• Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis.

  2012cited by this paper
• Lower airway microbiology and cellularity in children with newly diagnosed non‐CF bronchiectasis

  2012cited by this paper
• A multicenter study on chronic cough in children : burden and etiologies based on a standardized management pathway.

  2012cited by this paper
• The burden of disease in pediatric non-cystic fibrosis bronchiectasis.

  2012cited by this paper
• Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.

  2012cited by this paper
• Emerging drugs for bronchiectasis

  2012cited by this paper
• Pulmonary innate immunity in children with protracted bacterial bronchitis.

  2012cited by this paper
• Risk factors for morbidity and death in non-cystic fibrosis bronchiectasis: a retrospective cross-sectional analysis of CT diagnosed bronchiectatic patients

  2012cited by this paper
• The chronic bronchitis phenotype in subjects with and without COPD: the PLATINO study

  2012cited by this paper
• Bronchiectasis is associated with human T-lymphotropic virus 1 infection in an Indigenous Australian population.

  2012cited by this paper
• Emerging drugs for chronic obstructive pulmonary disease

  2012cited by this paper
• P172 Time Trends in Incidence and Prevalence of Bronchiectasis in the UK

  2012cited by this paper
• Nicotine receptor partial agonists for smoking cessation.

  2011cited by this paper
• Bronchiectasis: so much yet to learn and to do.

  2011cited by this paper
• Safety evaluation of sinus surfactant solution on respiratory cilia function

  2011cited by this paper
• Factors associated with bronchiectasis in patients with COPD.

  2011influential reference
• Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis.

  2011cited by this paper
• Nicotine receptor partial agonists for smoking cessation.

  2011cited by this paper
• Cannabinoid type 1 receptor antagonists for smoking cessation.

  2011cited by this paper
• The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study.

  2011cited by this paper
• Differences and similarities in non-cystic fibrosis bronchiectasis between developing and affluent countries.

  2011cited by this paper
• Effect of night symptoms and disease severity on subjective sleep quality in children with non‐cystic‐fibrosis bronchiectasis

  2011cited by this paper
• Expert patient self-management program versus usual care in bronchiectasis: a randomized controlled trial.

  2011cited by this paper
• Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases

  2011cited by this paper
• Implications of Host Genetic Variation on the Risk and Prevalence of Infectious Diseases Transmitted Through the Environment

  2011cited by this paper
• Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand

  2011cited by this paper
• Breathing in America: Diseases, Prognosis, and Hope

  2011cited by this paper
• British Thoracic Society guideline for non-CF bronchiectasis

  2010influential reference
• Longitudinal growth and lung function in pediatric non-CF bronchiectasis - what influences lung function stability?

  2010cited by this paper
• Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993-2006.

  2010cited by this paper
• Hospitalisation of Indigenous children in the Northern Territory for lower respiratory illness in the first year of life

  2010cited by this paper
• Bronchoarterial ratio on high-resolution CT scan of the chest in children without pulmonary pathology: need to redefine bronchial dilatation.

  2010cited by this paper
• British Thoracic Society guideline for non-CFbronchiectasis

  2010cited by this paper
• Comparison between conventional interrupted high-resolution CT and volume multidetector CT acquisition in the assessment of bronchiectasis.

  2010cited by this paper
• Trends in bronchiectasis mortality in England and Wales.

  2010influential reference
• High prevalence of bronchiectasis in adults: analysis of CT findings in a health screening program.

  2010cited by this paper
• Dornase alfa for cystic fibrosis.

  2010cited by this paper
• Respiratory bacterial pathogens in the nasopharynx and lower airways of Australian indigenous children with bronchiectasis.

  2010cited by this paper
• Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD.

  2010cited by this paper
• Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. A position statement from the Thoracic Society of Australia and New Zealand and the Australian Lung Foundation

  2010cited by this paper
• Effect of mannitol and repetitive coughing on the sputum properties in bronchiectasis.

  2010cited by this paper
• Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis.

  2010cited by this paper
• Azithromycin induces anti-viral responses in bronchial epithelial cells

  2010cited by this paper
• Bronchoalveolar lavage fluid microbiology and airway cellularity in children with newly diagnosed bronchiectasis

  2010cited by this paper
• Can a management pathway for chronic cough in children improve clinical outcomes: protocol for a multicentre evaluation

  2010cited by this paper
• Diagnosing and preventing chronic suppurative lung disease (CSLD) and bronchiectasis

  2010cited by this paper

• Recommended Reading from the Fondazione Policlinico Universitario A. Gemelli IRCCS Fellows.

  2019cites this paper
• Pharmacotherapeutic strategies for treating bronchiectasis in pediatric patients

  2019cites this paper
• INVITED REVIEW SERIES: PAEDIATRIC AND ADULT BRONCHIECTASIS

  2018cites this paper
• Bronchiectasis and Chronic Suppurative Lung Disease

  2018cites this paper
• Bronchiectasis in children: diagnosis and treatment.

  2018cites this paper
• An update on pediatric bronchiectasis

  2017cites this paper
• Pediatric bronchiectasis: No longer an orphan disease

  2016cites this paper
• Bronchiectasis: Current Concepts in Pathogenesis, Immunology, and Microbiology.

  2016cites this paper
• Efficacy of inhaled ciprofloxacin in the management of non-cystic fibrosis bronchiectasis

  2013cites this paper